Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.

• Published in: European Urology
• Main Authors: Sigurdardottir, Lara G, Markt, Sarah C, Rider, Jennifer R, Haneuse, Sebastien, Fall, Katja, Schernhammer, Eva S, Tamimi, Rulla M, Flynn-Evans, Erin, Batista, Julie L, Launer, Lenore, Harris, Tamara, Aspelund, Thor, Stampfer, Meir J, Gudnason, Vilmundur, Czeisler, Charles A, Lockley, Steven W, Valdimarsdottir, Unnur A, Mucci, Lorelei A
• Other Authors: 1 Univ Iceland, Ctr Publ Hlth Sci, Reykjavik, Iceland 2 Univ Iceland, Fac Med, Reykjavik, Iceland 3 Iceland Canc Soc, Reykjavik, Iceland 4 Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA 5 Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA 6 Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA 7 Univ Orebro, Clin Epidemiol Unit, SE-70182 Orebro, Sweden 8 Orebro Univ Hosp, SE-70182 Orebro, Sweden 9 Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02115 USA 10 Brigham & Womens Hosp, Dept Med, Div Sleep & Circadian Disorders, Boston, MA 02115 USA 11 Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA 12 Natl Inst Aging, Lab Epidemiol & Populat Sci, Bethesda, MD USA 13 Iceland Heart Assoc, Kopavogur, Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier Science BV 2016
• Subjects: Blöðruhálskirtilskrabbamein; Áhættuþættir; Svefn; Tíðni; Age Factors; Biomarkers; Down-Regulation; Humans; Iceland; Incidence; Male; Melatonin; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Risk Factors; Sleep; Sleep Wake Disorders; Time Factors
• Online Access: http://hdl.handle.net/2336/605261; https://doi.org/10.1016/j.eururo.2014.07.008

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access. Melatonin has anticarcinogenic properties in experimental models. We undertook a case-cohort study of 928 Icelandic men without prostate cancer (PCa) nested within the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the prospective association between first morning-void urinary 6-sulfatoxymelatonin (aMT6s) levels and the subsequent risk for PCa, under the hypothesis that men with lower aMT6s levels have an increased risk for advanced PCa. We used weighted Cox proportional hazards models to assess the association between first morning-void aMT6s levels and PCa risk, adjusting for potential confounders. A total of 111 men were diagnosed with incident PCa, including 24 with advanced disease. Men who reported sleep problems at baseline had lower morning aMT6s levels compared with those who reported no sleep problems. Men with morning aMT6s levels below the median had a fourfold statistically significant increased risk for advanced disease compared with men with levels above the median (hazard ratio: 4.04; 95% confidence interval, 1.26-12.98). These results require replication in larger prospective studies with longer follow-up. In this report, we evaluated the prospective association between urinary aMT6s levels and risk of PCa in an Icelandic population. We found that lower levels of aMT6s were associated with an increased risk for advanced PCa. RANNIS (the Icelandic Research Fund) National Institutes of Health (NIH) National Center for Research Resources UL1-RR-025758 KL2-RR-025757 Icelandic Cancer Society NIH National Cancer Institute R25-CA-098566 T32-CA-09001-35 Prostate Cancer Foundation NIH National Institutes on Aging (NIA) N01-AG-12100 Icelandic Heart Association Icelandic Parliament NIH NIA P01-AG-009975